SECTOR REVIEW

HEALTHCARE

CONTRIBUTION TO GROUP











Hemas Healthcare Sector is one of Sri Lanka's largest private healthcare providers with a strong presence across the healthcare value chain.

The largest pharmaceutical distribution operation in the country representing over 50 global principals through its well-established distribution network.

Pharmaceutical Manufacturing

Pharmaceutical Distribution

One of the largest private pharmaceutical manufacturers in the country focusing on building homegrown brands, having a world class manufacturing facility.

Hospitals

Profit Before Tax

45.3%

Two multi-specialty hospitals accredited by the Australian Council on Healthcare Standards International and chain of medical laboratories.



SLFRS S2 Indicators

Pharmaceutical Distribution No. of pharmacy locations 3,200+

Total area of retail space 850,000 m²

Number of surgical units sold (Both Surgicals and diagnostics)

6,133,221 units Number of pharmacists

8,000+

148

Number of pharmaceutical units sold 43,075,775 units

Hospitals

Number of Facilities 2 Hospitals

- Wattala 129 Beds, Thalawathugoda - 79 Beds Labs - **25**
- Collection Centers 19

In patient admissions 17,593

Out patient visits 453,279



PHARMACEUTICAL DISTRIBUTION

- Well established with over seven decades of existence
- Strong and enduring partnerships with principals
- Offering a wide range of products Sustained market leadership
- Wide distribution and sales network spanning the entire country

PHARMACEUTICAL MANUFACTURING

- Trusted household Over the Counter (OTC)/ consumer range
- The new state-of-th-art wordlclass pharma manufacturing facility at Homagama
- Healthy traction for Morison's new branded pharma range with a unique value blend - EmpaMor is now the highest selling Empagliflozin brand in SL
- Strong new product development pipeline in the Non-Communicable Diseases (NCD) space with niche novel molecules
- Synergies of being part of the Hemas Healthcare ecosystem

HOSPITALS

- Trusted Healthcare brand (since 2007)
- Located in underserved areas, having
- high potential Achieved operational excellence
- Provision of a wide variety of services
- & specialities
- Lab network and sample collection centers currently in 44 key locations

PERFORMANCE HIGHLIGHTS



ROCE 22.3% (FY 24: 14.7%)



• Price fluctuations due to volatility in world market prices and exchange rates.

formula Reduce working capital requirement through enhanced working cycle

PHARMACEUTICAL MANUFACTURING management

PHARMACEUTICAL MANUFACTURING

PHARMACEUTICAL DISTRIBUTION

medicines and medical equipment

Increase partnerships to provide

Leading the consultations with

stakeholders on industry matters

such as the finalisation of the pricing

greater range and the latest

- Ensuring strict quality standards with a patient centric approach
- Entry into the cardiovascular segment with three promising advanced molecules. Intensified focus on pharmaceutical
 - manufacturing and brand building
 - Liaise with industry bodies to develop a strong policy framework for pharmaceutical manufacturing
 - Partnership with the Sri Lanka College of Endocrinologists (SLCE), to launch a training course for primary healthcare professionals on diabetes management


HOSPITALS

- care
- Digitisation initiatives
- healthcare education
- Land acquired for Thalawathugoda hospital expansion

Rs. 69,988Mn

ACTION







- Lack of clear and consistent policies to support the development of local pharma manufacturing industry
- Lack of a proper promotional code for pharmaceutical marketing creates challenges when attempting to increase awareness about the benefits and standards of our products among the medical fraternity
- Intense competition
- Retention of skilled and trained staff
- · Inherent capital intensive nature of the industry with higher payback periods

HOSPITALS

Relatively smaller player

technologies

- Retention of skilled staff • Increasing cost of healthcare and reduced purchasing power impacting
- overall demand Constantly evolving and emerging
 - - Tie up with SLIIT to promote

 Introduction of new specialities (Cardiology) Introduction of new services - Home







WAY FORWARD



PHARMACEUTICAL DISTRIBUTION

- Finalise and operationalise the pricing formula in a manner which is fair for all stakeholders
- Increase distribution network
- Explore more partnerships with the added objective of addressing underleveraged areas of strategic interest to further strengthen its market position.

PHARMACEUTICAL MANUFACTURING

- Pursue EU GMP accreditation
- Further strengthen the new product development pipeline
- Explore export opportunities
- Conducting capability building initiatives for teams
- Strengthen engagement with the medical fraternity with a meaningful and professional approach

HOSPITALS

- Increase in insurance penetration will drive greater demand for private healthcare
- Expansion of the Thalawathugoda hospital
- Capacity and Government spending constraints provides an opportunity for the Private sector to step in.
- Introduction of new specialities such as Oncology and Neurology
- Further expand the Lab network

CRAFTING PROSPERITY

149